Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma

References

1. 1.↵
   2. Dodd GD 3rd.,
   3. Allen B Jr.,
   4. Birzniek D, et al

   . Reengineering the radiology enterprise: a summary of the 2014 Intersociety Committee Summer Conference. J Am Coll Radiol 2015;12:228–34 doi:10.1016/j.jacr.2014.11.022 pmid:25743920

   CrossRefPubMed
2. 2.↵
   2. Mitchell DG,
   3. Bruix J,
   4. Sherman M, et al

   . LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015;61:1056–65 doi:10.1002/hep.27304 pmid:25041904

   CrossRefPubMed
3. 3.↵
   2. Weinreb JC,
   3. Barentsz JO,
   4. Choyke PL, et al

   . PI-RADS Prostate Imaging-Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16–40 doi:10.1016/j.eururo.2015.08.052 pmid:26427566

   CrossRefPubMed
4. 4.↵
   2. Cheng SP,
   3. Lee JJ,
   4. Lin JL, et al

   . Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TI-RADS). Head Neck 2013;35:541–47 doi:10.1002/hed.22985 pmid:22514060

   CrossRefPubMed
5. 5.↵
   2. Aiken AH,
   3. Farley A,
   4. Baugnon KL, et al

   . Implementation of a novel surveillance template for head and neck cancer: Neck Imaging Reporting and Data System (NI-RADS). J Am Coll Radiol 2016;13:743–46.e1 doi:10.1016/j.jacr.2015.09.032 pmid:26577876

   CrossRefPubMed
6. 6.↵
   2. Leung AS,
   3. Rath TJ,
   4. Hughes MA, et al

   . Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinoma. Head Neck 2016;38(suppl 1):E853–58 doi:10.1002/hed.24112 pmid:25917499

   CrossRefPubMed
7. 7.↵
   2. Gilbert MR,
   3. Branstetter BF 4th.,
   4. Kim S

   . Utility of positron-emission tomography/computed tomography imaging in the management of the neck in recurrent laryngeal cancer. Laryngoscope 2012;122:821–25 doi:10.1002/lary.22428 pmid:22344673

   CrossRefPubMed
8. 8.↵
   2. Koshkareva Y,
   3. Branstetter BF 4th.,
   4. Gaughan JP, et al

   . Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. Laryngoscope 2014;124:1843–47 doi:10.1002/lary.24617 pmid:24474646

   CrossRefPubMed
9. 9.↵
   2. McDermott M,
   3. Hughes M,
   4. Rath T, et al

   . Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer. AJNR Am J Neuroradiol 2013;34:1632–36 doi:10.3174/ajnr.A3494 pmid:23639557

   Abstract/FREE Full Text
10. 10.↵
    2. Pfister DG,
    3. Spencer S,
    4. Brizel DM, et al

    ; National Comprehensive Cancer Network. Head and neck cancers, Version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2014;12:1454–87 pmid:25313184

    Abstract/FREE Full Text
11. 11.↵
    2. Roman BR,
    3. Patel SG,
    4. Wang MB, et al

    . Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. J Natl Compr Canc Netw 2015;13:69–77 pmid:25583771

    Abstract/FREE Full Text
12. 12.↵
    2. Ho AS,
    3. Tsao GJ,
    4. Chen FW, et al

    . Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer 2013;119:1349–56 doi:10.1002/cncr.27892 pmid:23225544

    CrossRefPubMed
13. 13.↵
    2. Ong SC,
    3. Schöde H,
    4. Lee NY, et al

    . Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49:532–40 doi:10.2967/jnumed.107.044792 pmid:18344440

    Abstract/FREE Full Text